
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
Keywords: سورفانیب; Cancer; Renal cell cancer; Vascular endothelial growth factor; Sunitinib; Sorafenib; Pazopanib; Vandetanib; Meta-analysis; Mortality; Fatal adverse events;